Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.58 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 2/20 | 0.40 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22482999 | 0.87 | HDAC6 (0.48) | HDAC6HDAC8HDAC11HDAC3P2RX3 | |
| SCHEMBL24473205 | 0.82 | GSTP1 (0.42) | HDAC6HDAC8HDAC11HDAC3P2RX3 | |
| SCHEMBL22482879 | 0.82 | HDAC6 (0.56) | HDAC6HDAC8HDAC11HDAC3P2RX3 | |
| SCHEMBL22483039 | 0.82 | HDAC6 (0.47) | HDAC6HDAC8HDAC11HDAC3P2RX3 | |
| SCHEMBL22482998 | 0.79 | HDAC6 (0.55) | HDAC6HDAC8HDAC11HDAC3 | |
| SCHEMBL22483031 | 0.78 | HDAC6 (0.62) | HDAC6HDAC8HDAC11HDAC3P2RX3 | |
| SCHEMBL19021370 | 0.77 | GSTP1 (0.48) | P2RX3GSTP1GSTM2 | |
| SCHEMBL19167335 | 0.77 | GSTP1 (0.48) | P2RX3GSTP1GSTM2 | |
| SCHEMBL1350794 | 0.76 | GSTP1 (0.48) | P2RX3GSTP1GSTM2 | |
| SCHEMBL24473144 | 0.75 | GSTP1 (0.43) | HDAC6P2RX3GSTP1GSTM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169598-A1 | HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORS | 2681603 ONTARIO INC. (CA) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169598-A1 | HALOGENATED PHENYLSULFONAMIDE HYDROXAMIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF AS SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC11 | HDAC6 1/4885HDAC8 11/4885HDAC11 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.